[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015008037A2 - compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção - Google Patents

compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção

Info

Publication number
BR112015008037A2
BR112015008037A2 BR112015008037A BR112015008037A BR112015008037A2 BR 112015008037 A2 BR112015008037 A2 BR 112015008037A2 BR 112015008037 A BR112015008037 A BR 112015008037A BR 112015008037 A BR112015008037 A BR 112015008037A BR 112015008037 A2 BR112015008037 A2 BR 112015008037A2
Authority
BR
Brazil
Prior art keywords
compound
compounds
preparing
pharmaceutical composition
treating cancer
Prior art date
Application number
BR112015008037A
Other languages
English (en)
Inventor
Zhou Chengang
Wang Jianhua
Jiang Min
Wang Min
Yang Song
Han Xingchun
Cheng Zhanling
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015008037A2 publication Critical patent/BR112015008037A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

resumo “compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção” a presente invenção se refere aos compostos inovadores que possuem a fórmula geral, em que r1, r2 e r3 são conforme descritos no presente, às composições incluindo os compostos e aos métodos de utilização dos compostos.
BR112015008037A 2012-12-10 2013-12-06 compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção BR112015008037A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/086275 2012-12-10
PCT/EP2013/075751 WO2014090692A1 (en) 2012-12-10 2013-12-06 Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112015008037A2 true BR112015008037A2 (pt) 2017-07-04

Family

ID=49713100

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008037A BR112015008037A2 (pt) 2012-12-10 2013-12-06 compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção

Country Status (10)

Country Link
US (1) US20150266878A1 (pt)
EP (1) EP2928893A1 (pt)
JP (1) JP2016501251A (pt)
KR (1) KR20150092279A (pt)
BR (1) BR112015008037A2 (pt)
CA (1) CA2885392A1 (pt)
HK (1) HK1213544A1 (pt)
MX (1) MX2015007097A (pt)
RU (1) RU2015124917A (pt)
WO (1) WO2014090692A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3183239B1 (en) * 2014-08-22 2018-09-26 Merck Patent GmbH Indazoles
CN104610229B (zh) * 2015-01-21 2017-01-18 上海皓元生物医药科技有限公司 一种是atp竞争性小分子akt抑制剂a443654的合成方法
KR20180073600A (ko) 2015-11-03 2018-07-02 루 라이센스 에이비 과증식성 장애의 치료를 위한 화합물
US11578067B2 (en) 2017-01-30 2023-02-14 Kyoto University Compound, and method for producing regulatory T cells
US11261184B2 (en) 2017-10-02 2022-03-01 Boehringer Ingelheim International Gmbh [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors
CN111936490A (zh) 2017-11-20 2020-11-13 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019192903A1 (de) * 2018-04-06 2019-10-10 Basf Se Verfahren zur herstellung von aminen
US20220162182A1 (en) * 2018-12-31 2022-05-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20210147441A1 (en) * 2019-09-26 2021-05-20 Agency For Science, Technology And Research (A*Star) Therapeutic compounds and methods of use thereof
US20230234935A1 (en) * 2020-06-26 2023-07-27 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
AR127141A1 (es) 2021-09-27 2023-12-20 Univ Kyoto Método para producir células t
KR20240116751A (ko) 2021-11-24 2024-07-30 레그셀 가부시키가이샤 사람 유도성 제어성 t세포 및 그 제작 방법
MX2024006370A (es) 2021-11-24 2024-08-19 Regcell Co Ltd Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t.
WO2023182328A1 (ja) 2022-03-23 2023-09-28 国立大学法人京都大学 制御性ｔ細胞の製造方法
WO2024128741A1 (en) * 2022-12-12 2024-06-20 Avelos Therapeutics Inc. Substituted heterocyclic compound derivatives and their pharmaceutical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516196A (ja) * 2003-07-02 2007-06-21 ガラパゴス エヌブイ Ｒｈｏキナーゼ阻害剤としてのピラジン及びピラリジン誘導体
US20090196912A1 (en) * 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
AU2005309616A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
JP2009507843A (ja) * 2005-09-09 2009-02-26 シェーリング コーポレイション アザ縮合サイクリン依存性キナーゼ阻害剤
US8367671B2 (en) * 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents

Also Published As

Publication number Publication date
KR20150092279A (ko) 2015-08-12
JP2016501251A (ja) 2016-01-18
US20150266878A1 (en) 2015-09-24
HK1213544A1 (zh) 2016-07-08
EP2928893A1 (en) 2015-10-14
MX2015007097A (es) 2015-09-29
CA2885392A1 (en) 2014-06-19
RU2015124917A (ru) 2017-01-12
WO2014090692A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
BR112012027509A8 (pt) Composto pirazolil-quinoxalina inibidor de quinase, combinação, produto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e método
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112018001400A2 (pt) compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
BRPI1009637A2 (pt) composto, composição e uso de um composto
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
BR112017026132A2 (pt) piridinas substituídas e métodos de uso
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
BR112015014583B1 (pt) compostos, processo para a preparação de compostos, compostos intermediários, composição, usos de um composto de fórmula i e método para combater fungos nocivos
BR112018006519A2 (pt) compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente
BRPI1014802B8 (pt) profármacos de triptolida.
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
BR112017028322A2 (pt) compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
BR112018010140A2 (pt) compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)